细菌噬菌体疗法市场规模、价值及截至2029年的收入分析

市场分析和规模

抗生素耐药性在世界范围内变得越来越普遍，这推动了对有效替代品的需求。据美国疾病控制与预防中心称，抗生素耐药性细菌感染每年影响欧洲约 33,000 人。预计抗生素耐药性将在全球范围内增加，从而对噬菌体产生大量需求。噬菌体疗法是噬菌体疗法的另一个名称。为了治疗细菌感染，人们使用病毒。噬菌体是细菌病毒。噬菌体是杀菌病毒，对植物、动物和人类无害。噬菌体被认为是细菌的天敌。噬菌体存在于污水、水、土壤和其他存在细菌的环境中。

Data Bridge Market Research 分析称，2021 年噬菌体治疗市场价值为 3980 万美元，预计到 2029 年将达到 6440 万美元，在 2022 年至 2029 年的预测期内复合年增长率为 6.20%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

报告指标	细节
预测期	2022 至 2029 年
基准年	2021
历史岁月	2020（可定制为 2014 - 2019）
定量单位	收入（百万美元）、销量（单位）、定价（美元）
涵盖的领域	目标（大肠杆菌、葡萄球菌、链球菌、假单胞菌、沙门氏菌等）、类型（溶菌性、溶原性）、基质（无菌肉汤培养物、水溶性果冻基质）、应用（细菌性痢疾、皮肤和鼻粘膜感染、化脓性皮肤感染、肺和胸膜感染、术后伤口感染等）、给药途径（口服、肠胃外、直肠、皮肤、其他）、最终用户（医院、专科诊所、家庭护理、其他）、分销渠道（医院药房、零售药房、网上药房、其他）
覆盖国家	U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
Market Players Covered	Microgen (U.S.), Micreos (Netherlands), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics (U.S.), Armata pharmaceuticals Inc. (U.S.),LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Nextbiotics (U.S.), Pherecydes Pharma (France), iNtODEWORLD. Inc. (U.S.), Enbiotix (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Eliava Bio Preparations LTD (Georgia), Phagelux, Inc. (China), InnoPhage, Ltd (Hong Kong), TechnoPhage (Portugal), Eligo Bioscience SA (France), BiomX Ltd. (Israel)
Market Opportunities	Increase in the number of research and development activities Rising technological advancement

Market Definition

Bacteriophages, are viruses that kill and target bacteria exclusively. They're one of the most frequent biological entities capable of fighting and killing multidrug-resistant bacteria. When all other antibiotics have failed to treat an infection, phages can eliminate the bacteria causing the infection, allowing medical experts to save a life. Bacteriophages are being considered an antibiotic replacement. Viruses are employed in this therapy to inject their genetic material into bacteria and grow using their host machinery. This phage therapy is utilized in the body of patients to cure or prevent bacterial diseases. Bacteriophage therapy is also important in the disciplines of molecular biology and technological research. These characteristics broaden the possibility for medication development. Bacteriophages are also termed as Phages.

Bacteriophages Therapy Market Dynamics

Drivers

High prevalence rate of foodborne diseases

The rise in prevalence rate of foodborne diseases across the globe will act as a major driver that will result in the expansion of the market's growth rate. Foodborne infections caused by spoiled food are becoming more common. Pathogenic bacteria and viruses are present in spoiled food. According to the WHO, about 600 million people (almost one out of every ten people on the planet) will become ill and 420,000 will die as a result of contaminated food in 2019, resulting in the loss of 33 million healthy life years (DALYs). Furthermore, children under the age of five years bear 40% of the burden of foodborne disease, with 125,000 deaths every year. This aspect is propelling the bacteriophages therapy market forward.

Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of bacteriophages therapy market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Growing prevalence of antibiotic-resistant infections

Growing prevalence of antibiotic-resistant infections is expected to enhance the market's growth. The rising prevalence of antimicrobial-resistant infections has resulted in increased healthcare spending for their treatment and an increase in the number of deaths. According to the Centers for Disease Control and Prevention (CDC), approximately 2 million people in the United States will contract an antibiotic-resistant infection in 2019, with at least 23,000 people dying each year. As per the World Health Organization, over 490,000 persons worldwide were infected with multidrug-resistant tuberculosis in 2016. This drug resistance complicates the management of people suffering from other diseases including malaria and HIV.

Furthermore, a surging number of government initiatives to spread awareness and increasing the geriatric population will result in the expansion of the bacteriophages therapy market. Along with this, changing lifestyle of people and increasing level of disposable income will enhance the growth rate of the market.

Opportunities

Increase in the number of research and development activities

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the bacteriophages therapy market growth. For instance, in January 2019, the US Food and Drug Administration approved a request from physician-scientists at the University Of California San Diego School Of Medicine to perform the first U.S. clinical trial of a bacteriophage-based therapy administered intravenously. The planned experiment will be carried out in partnership with AmpliPhi Biosciences Corporation, a biotechnology firm based in San Diego.

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the bacteriophages therapy market growth.

Restraints/Challenges

On the other hand, the high cost associated with bacteriophages therapy will obstruct the growth rate of bacteriophages therapy market during the forecast period of 2022-2029. The lack of healthcare infrastructure in developing economies and strict regulatory scenario will challenge the bacteriophages therapy market. Additionally, lack of awareness among people and availability of alternatives will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This bacteriophages therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the bacteriophages therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Bacteriophages therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Bacteriophages Therapy Market

The disease has spread to over 100 nations since the COVID-19 viral outbreak in December 2019, prompting the World Health Organization to designate it a public health emergency. Furthermore, the COVID-19 pandemic posed significant challenges to companies in the worldwide bacteriophage therapy market on multiple fronts. Supply of raw materials for producing medication formulations was a big difficulty because to transportation facility inconsistencies. Furthermore, due to a rising patient population suffering from COVID-19 and other life-threatening conditions, goods distributors were encountering erratic demand from retailers. The COVID-19 pandemic disrupted clinical trials in the United States, affecting important players across the sector. Staff furloughs, social-distancing protocols, financial losses, and concerns about patient safety all impacted investigative site capabilities. Sponsors, CROs, and other drug development support businesses have moved to remote working environments. As a result of the COVID-19 pandemic, an estimated 80% of non-COVID-19 trials were halted or interrupted.

Global Bacteriophages Therapy Market Scope

The bacteriophages therapy market is segmented on the basis of target, type, base, application, route of administration, end-user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Target

Escherichia Coli
Staphylococcus
Streptococcus
Pseudomonas
Salmonella
Others

Type

Lytic
Lysogenic

Base

Sterile Broth Culture
Water-Soluble Jelly Base

Application

Bacterial Dysentery
皮肤和鼻粘膜感染
化脓性皮肤感染
肺部和胸膜感染
术后伤口感染
其他的

给药途径

口服
肠外
直肠
皮肤
其他的

最终用户

医院
专科诊所
家庭护理
其他的

分销渠道

医院药房
零售药店
网上药店
其他的

噬菌体治疗市场区域分析/见解

对噬菌体治疗市场进行了分析，并按国家、目标、类型、基础、应用、给药途径、最终用户和分销渠道提供了市场规模洞察和趋势。

噬菌体治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在市场份额和市场收入方面占据噬菌体治疗市场的主导地位，并将在预测期内继续保持主导地位。这是因为溶菌噬菌体提供的即时恢复和治疗效果以及不断增长的医疗保健支出将进一步推动该地区市场的增长率。此外，主要关键参与者的存在和新技术的采用率的提高将进一步推动该地区市场的增长率。

由于亚太地区对新型药物创新研发的投资不断增加，预计该地区将成为 2022-2029 年预测期内增长最快的地区。此外，医疗基础设施的发展和政府举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和噬菌体治疗市场份额分析

噬菌体治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对噬菌体治疗市场的关注有关。

噬菌体治疗市场的一些主要参与者包括：

Microgen (美国)
Micreos（荷兰）
ATCC（美国）
Intralytix, Inc.（美国）
Adaptive Phage Therapeutics（美国）
Armata pharmaceuticals Inc.（美国）
LOCUS BIOSCIENCES, INC.（美国）
Delmont Laboratories, Inc.（美国）
Nextbiotics (美国)
Pherecydes Pharma（法国）
intODEWORLD. Inc.（美国）
Enbiotix（美国）
Fixed-Phage Limited（英国）
Cytophage Technologies Inc.（加拿大）
Eliava Bio Preparations LTD（格鲁吉亚）
Phagelux, Inc. (中国)
InnoPhage 有限公司 (香港)
TechnoPhage（葡萄牙）
Eligo Bioscience SA（法国）
BiomX Ltd.（以色列）

SKU-59408

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 2 GLOBAL STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 3 GLOBAL ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 4 GLOBAL PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 5 GLOBAL STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 6 GLOBAL SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 7 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 GLOBAL LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 10 GLOBAL LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 11 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 12 GLOBAL STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 13 GLOBAL WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 14 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 15 GLOBAL POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 16 GLOBAL INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 17 GLOBAL BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 18 GLOBAL SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 19 GLOBAL LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 20 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 22 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 23 GLOBAL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 24 GLOBAL DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 25 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 26 GLOBAL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 27 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 29 GLOBAL HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 30 GLOBAL SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 31 GLOBAL ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 32 GLOBAL OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 34 GLOBAL DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 35 GLOBAL THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 37 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 38 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 39 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 40 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 41 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 42 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 43 NORTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 44 NORTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 45 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 46 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 47 U.S. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 48 U.S. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 49 U.S. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 50 U.S. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 51 U.S. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 52 U.S. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 53 U.S. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 54 U.S. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 55 U.S. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 56 CANADA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 57 CANADA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 58 CANADA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 59 CANADA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 CANADA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 61 CANADA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 62 CANADA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 63 CANADA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 64 CANADA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 65 EUROPE BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 66 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 67 EUROPE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 68 EUROPE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 69 EUROPE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 70 EUROPE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 71 EUROPE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 72 EUROPE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 73 EUROPE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 74 EUROPE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 75 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 76 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 77 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 78 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 79 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 80 GEORGIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 81 GEORGIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 82 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 83 GEORGIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 84 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 85 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 86 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 87 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 88 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 89 RUSSIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 90 RUSSIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 91 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 92 RUSSIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 93 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 94 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 95 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 96 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 97 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 98 BELGIUM ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 99 BELGIUM PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 100 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 101 BELGIUM BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 102 POLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 103 POLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 104 POLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 105 POLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 106 POLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 107 POLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 108 POLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 109 POLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 110 POLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 111 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 112 FRANCE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 113 FRANCE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 114 FRANCE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 115 FRANCE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 116 FRANCE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 117 FRANCE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 118 FRANCE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 119 FRANCE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 120 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 121 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 123 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 124 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 125 NETHERLANDS ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 126 NETHERLANDS PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 127 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 128 NETHERLANDS BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 129 U.K. BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 130 U.K. BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 131 U.K. BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 132 U.K. BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 133 U.K. BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 134 U.K. ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 135 U.K. PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 136 U.K. BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 137 U.K. BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 138 ITALY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 139 ITALY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 140 ITALY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 141 ITALY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 142 ITALY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 143 ITALY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 144 ITALY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 145 ITALY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 146 ITALY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 147 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 148 GERMANY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 149 GERMANY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 150 GERMANY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 GERMANY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 152 GERMANY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 153 GERMANY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 154 GERMANY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 155 GERMANY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 156 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 157 TURKEY BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 TURKEY BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 159 TURKEY BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 160 TURKEY BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 161 TURKEY ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 162 TURKEY PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 163 TURKEY BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 164 TURKEY BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 165 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 166 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 167 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 168 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 169 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 170 SWITZERLAND ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 171 SWITZERLAND PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 172 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 173 SWITZERLAND BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 174 REST OF EUROPE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 175 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 176 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 177 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 178 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 179 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 180 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 181 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 182 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 183 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 184 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 185 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 186 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 187 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 188 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 189 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 190 SOUTH AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 191 SOUTH AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 192 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 193 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 194 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 195 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 197 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 198 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 199 SAUDI ARABIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 200 SAUDI ARABIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 201 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 202 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 203 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 204 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 205 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 206 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 207 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 208 ISRAEL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 209 ISRAEL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 210 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 211 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 212 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 213 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 214 EGYPT BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 215 EGYPT BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 216 EGYPT BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 217 EGYPT ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 218 EGYPT PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 219 EGYPT BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 220 EGYPT BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 221 REST OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 222 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 223 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 224 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 225 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 226 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 227 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 228 ASIA-PACIFIC ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 229 ASIA-PACIFIC PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 230 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 231 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 232 CHINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 233 CHINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 234 CHINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 235 CHINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 236 CHINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 237 CHINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 238 CHINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 239 CHINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 240 CHINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 241 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 242 JAPAN BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 243 JAPAN BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 244 JAPAN BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 245 JAPAN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 246 JAPAN ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 247 JAPAN PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 248 JAPAN BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 249 JAPAN BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 250 INDIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 251 INDIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 252 INDIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 253 INDIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 254 INDIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 255 INDIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 256 INDIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 257 INDIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 INDIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 259 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 260 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 261 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 262 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 263 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 264 AUSTRALIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 265 AUSTRALIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 266 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 267 AUSTRALIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 268 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 269 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 271 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 272 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 273 SOUTH KOREA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 274 SOUTH KOREA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 275 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 SOUTH KOREA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 277 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 278 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 279 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 280 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 281 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 282 SINGAPORE ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 283 SINGAPORE PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 284 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 SINGAPORE BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 286 REST OF ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 287 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 288 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 289 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 290 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 291 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 292 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 293 SOUTH AMERICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 294 SOUTH AMERICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 295 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 296 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 297 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 298 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 299 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 300 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 301 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 302 BRAZIL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 303 BRAZIL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 304 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 305 BRAZIL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 306 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

TABLE 307 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 308 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)

TABLE 309 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 310 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 311 ARGENTINA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 312 ARGENTINA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)

TABLE 313 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 314 ARGENTINA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 315 REST OF SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 GLOBAL BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 2 GLOBAL BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL BACTERIOPHAGES THERAPY MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 GLOBAL BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL BACTERIOPHAGES THERAPY MARKET: SEGMENTATION

FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE GLOBAL BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028

FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET FOR STEM CELL MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL BACTERIOPHAGES THERAPY MARKET

FIGURE 16 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020

FIGURE 17 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)

FIGURE 18 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)

FIGURE 19 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE

FIGURE 20 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020

FIGURE 21 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 22 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 23 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE

FIGURE 24 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020

FIGURE 25 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)

FIGURE 26 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)

FIGURE 27 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE

FIGURE 28 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020

FIGURE 29 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 30 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 31 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 32 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020

FIGURE 33 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)

FIGURE 34 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)

FIGURE 35 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020

FIGURE 37 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 41 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 45 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2020)

FIGURE 46 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2021 & 2028)

FIGURE 47 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY REGION (2020 & 2028)

FIGURE 48 GLOBAL BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 49 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 50 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 51 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 52 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 53 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 54 EUROPE BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 55 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 56 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 57 EUROPE BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 58 EUROPE BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 59 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 60 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 61 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 62 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 63 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 64 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 65 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 66 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 67 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 68 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 69 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)

FIGURE 70 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)

FIGURE 71 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)

FIGURE 72 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)

FIGURE 73 SOUTH AMERICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)

FIGURE 74 GLOBAL BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

FIGURE 75 NORTH AMERICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

FIGURE 76 EUROPE BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

FIGURE 77 ASIA-PACIFIC BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

How big is the Bacteriophages Therapy Market?

The Bacteriophages Therapy Market will be worth USD 64.40 million by 2029 during the forecast period.

What is the growth rate of the Bacteriophages Therapy Market?

The Bacteriophages Therapy Market growth rate is 6.20% during the forecast period.

What are the growth drivers of the Bacteriophages Therapy Market?

High prevalence rate of foodborne diseases, Increasing investment for healthcare infrastructure, and the Growing prevalence of antibiotic-resistant infections are the growth drivers of the Bacteriophages Therapy Market.

What are the factors on which the Bacteriophages Therapy Market research is based on?

The target, type, base, application, route of administration, end-user, and distribution channel are the factors on which the Bacteriophages Therapy Market research is based.

Which are the major companies in the Bacteriophages Therapy Market?

Major companies in the Bacteriophages Therapy Market are Microgen (U.S.), Micreos (Netherlands), ATCC (U.S.), Intralytix, Inc. (U.S.), Adaptive Phage Therapeutics (U.S.), Armata pharmaceuticals Inc. (U.S.),LOCUS BIOSCIENCES, INC. (U.S.), Delmont Laboratories, Inc. (U.S.), Nextbiotics (U.S.), Pherecydes Pharma (France), iNtODEWORLD. Inc. (U.S.), Enbiotix (U.S.), Fixed-Phage Limited (U.K.), Cytophage Technologies Inc. (Canada), Eliava Bio Preparations LTD (Georgia), Phagelux, Inc. (China), InnoPhage, Ltd (Hong Kong), TechnoPhage (Portugal), Eligo Bioscience SA (France), BiomX Ltd. (Israel).

Forecast Period	2022 –2029
Market Size (Base Year)	USD 39.80 Million
Market Size (Forecast Year)	USD 64.40 Million
CAGR	6.20 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

全球噬菌体治疗市场 – 行业趋势和 2029 年预测

全球噬菌体治疗市场 – 行业趋势和 2029 年预测

Global Bacteriophages Therapy Market

CAGR : 6.20 %

Bacteriophages Therapy Market Dynamics

COVID-19 Impact on Bacteriophages Therapy Market

Global Bacteriophages Therapy Market Scope

噬菌体治疗市场区域分析/见解

竞争格局和噬菌体治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

全球噬菌体治疗市场 – 行业趋势和 2029 年预测

全球噬菌体治疗市场 – 行业趋势和 2029 年预测

Global Bacteriophages Therapy Market

CAGR : 6.20 %

Bacteriophages Therapy Market Dynamics

COVID-19 Impact on Bacteriophages Therapy Market

Global Bacteriophages Therapy Market Scope

噬菌体治疗市场区域分析/见解

竞争格局和噬菌体治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面